硫酸镁治疗新生儿缺氧缺血性脑病的结局:系统评价与荟萃分析
该系统评价纳入20项RCT共1485例新生儿,评估硫酸镁作为神经保护剂在缺氧缺血性脑病中的作用。在未提供治疗性低温(TH)的环境中,硫酸镁未降低死亡率(RR 0.86,95%CI 0.72-1.03),但可能改善院内神经系统结局,如减少抽搐负担和改善出院时神经状态。与TH联用的研究未报告≥18月龄的死亡或神经发育残疾结局。
要点
- 在无TH环境中,硫酸镁未显著降低死亡率(RR 0.86,95%CI 0.72-1.03),证据确定性中等。
- 硫酸镁可能降低不良吸吮喂养风险(RR 0.52,95%CI 0.40-0.68)和异常脑电图风险(RR 0.64,95%CI 0.45-0.93)。
- 与TH联用时,硫酸镁与死亡率无关(RR 0.65,95%CI 0.34-1.27),但缺乏长期结局数据。
核心结论
- 硫酸镁治疗可能改善未接受TH新生儿的院内神经系统结局,但不影响死亡率。
- 硫酸镁联用或不联用TH的长期结局证据均匮乏,需要设计良好的RCT尤其低资源地区。
研究设计与样本
- 共纳入20项RCT,总样本量1485例,其中16项来自未提供治疗性低温(TH)的环境。
- 使用Stata 16.0和RevMan 5.3进行荟萃分析。
主要发现
- 在无TH环境中,仅1项研究评估≥18月龄死亡或残疾复合结局,对照组14例中8例、硫酸镁组8例中4例出现不良结局。
- 硫酸镁与死亡率无关(RR 0.86,95%CI 0.72-1.03;13项RCT)和低血压无关(RR 1.02,95%CI 0.88-1.18;5项RCT)。
- 13项研究报告硫酸镁改善院内结局如减少抽搐负担和改善出院神经状态。
- 硫酸镁降低不良吸吮喂养风险(RR 0.52,95%CI 0.40-0.68;6项RCT)和异常脑电图风险(RR 0.64,95%CI 0.45-0.93;5项RCT)。
- 以硫酸镁作为TH辅助的研究中,无研究报告≥18月龄死亡或神经发育残疾;硫酸镁与死亡率无关(RR 0.65,95%CI 0.34-1.27;3项RCT)和低血压无关(RR 1.0,95%CI 0.71-1.40;3项RCT)。
关键数值与推荐
- 死亡率证据确定性中等,其他结局证据确定性低或极低。
临床怎么用
- 在无TH条件下,硫酸镁可能作为改善院内神经系统结局的辅助治疗,但需权衡缺乏长期结局证据。
- 硫酸镁不增加死亡或低血压风险,但应与家长充分沟通长期证据的局限性。
- 在低资源地区开展设计良好的RCT以明确硫酸镁的神经保护作用和长期结局。
局限性
- 长期结局(≥18月龄死亡或残疾)证据匮乏,仅1项无TH环境研究提供数据。
- 多数结局证据确定性低或极低,尤其缺乏与TH联用的长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess magnesium sulfate (MgSO4) as a neuroprotective agent in hypoxic-ischemic encephalopathy. STUDY DESIGN: For this systematic review, PubMed, EMBASE, the Cochrane Library, EMCARE, and MedNar were searched in November 2022 for randomized controlled trials (RCTs). Meta-analysis was conducted using Stata 16.0 and RevMan 5.3. RESULTS: Twenty RCTs with a total sample size of 1485 were included, of which 16 were from settings where therapeutic hypothermia (TH) was not offered. Regarding MgSO4 in settings where TH was not offered, only 1 study evaluated composite outcome of death or disability at ≥18 months and reported such poor outcome in 8 of 14 control infants and 4 of 8 in the MgSO4 group. MgSO4 was not associated with mortality (RR, 0.86; 95% CI, 0.72-1.03; 13 RCTs) or hypotension (RR, 1.02; 95% CI, 0.88-1.18; 5 RCTs). Thirteen studies reported that MgSO4 improved in-hospital outcomes, such as reduced seizure burden and improved neurological status at discharge. MgSO4 reduced the risk of poor suck feeds (RR, 0.52; 95% CI, 0.40-0.68; 6RCTs) and abnormal electroencephalogram (RR, 0.64; 95% CI, 0.45-0.93; 5 RCTs). Certainty of evidence was moderate for mortality and low or very low for other outcomes. For studies with MgSO4 as an adjunct to TH, none reported on death or neurodevelopmental disability at ≥18 months. MgSO4 was not associated with mortality (RR, 0.65; 95% CI, 0.34-1.27; 3 RCTs) or hypotension (RR, 1.0; 95% CI, 0.71-1.40; 3 RCTs). CONCLUSIONS: Evidence around long-term outcomes of MgSO4 when used with or without TH was scant. MgSO4 therapy may improve in-hospital neurological outcomes without affecting mortality in settings where TH is not offered. Well-designed RCTs for neuroprotection are needed, especially in low-resource settings. TRIAL REGISTRATION: "Open Science Forum" (https://doi.org/10.17605/OSF.IO/FRM4D).
引用
- Gowda BB, Rath C, Muthusamy S, et al. Outcomes of Neonates with Hypoxic-Ischemic Encephalopathy Treated with Magnesium Sulfate: A Systematic Review with Meta-analysis. J Pediatr. 2023. PMID: 37468038. doi:10.1016/j.jpeds.2023.113610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。